<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of the Creative Commons Attribution 4.0 International license.mBio.02180-19.pdf Current seasonal" exact="influenza" post="vaccines are suboptimal and low in immunogenicity and do"/>
 <result pre="and do not provide long-lasting immunity and cross protection against" exact="influenza" post="virus strains that have antigenically drifted. More-effective influenza vaccines"/>
 <result pre="protection against influenza virus strains that have antigenically drifted. More-effective" exact="influenza" post="vaccines which can induce both humoral immunity and T"/>
 <result pre="and T cell immunity are needed. The NS1 protein of" exact="influenza" post="virus is a virulence element and the critical factor"/>
 <result pre="vaccines in humans. We have generated a panel of both" exact="influenza" post="A and influenza B DelNS1 LAIVs which are able"/>
 <result pre="We have generated a panel of both influenza A and" exact="influenza" post="B DelNS1 LAIVs which are able to grow in"/>
 <result pre="and emerging influenza. Abstract ABSTRACT Nonstructural protein 1 (NS1) of" exact="influenza" post="virus is a key virulence element with multifunctional roles"/>
 <result pre="would create a safer and more extensively immunogenic live attenuated" exact="influenza" post="virus (LAIV) vaccine. However, DelNS1 viruses are very difficult"/>
 <result pre="developed two master backbones of deleted-NS1 (DelNS1) viral genomes from" exact="influenza" post="A or B viruses which contain novel adaptive mutations"/>
 <result pre="nonpathogenic in mice but replicate well in vaccine-producing cells. Both" exact="influenza" post="A and influenza B DelNS1 LAIVs grow better at"/>
 <result pre="but replicate well in vaccine-producing cells. Both influenza A and" exact="influenza" post="B DelNS1 LAIVs grow better at 33°C than at"/>
 <result pre="strong long-lasting cross protection against heterosubtypic or antigenically distantly related" exact="influenza" post="viruses in mice. Mechanistic investigations revealed that DelNS1-LAIVs induce"/>
 <result pre="against seasonal and emerging influenza. KEYWORDS live attenuated vaccine NS1" exact="influenza" post="vaccines Funding Research Grant Council of Hong Kong SAR"/>
 <result pre="to alleviate the disease burden and mortality associated with seasonal" exact="influenza" post="and is also the method of choice to curb"/>
 <result pre="circulating strains makes it difficult to predict the evolution of" exact="influenza" post="viruses (IVs). An inability to induce long-lasting immunity and"/>
 <result pre="inability to induce long-lasting immunity and the effects of historical" exact="influenza" post="virus infections on vaccine-induced immune responses further complicate the"/>
 <result pre="responses further complicate the current vaccine strategy. Mismatch of seasonal" exact="influenza" post="vaccines and circulating strains occurs regularly, resulting in severe"/>
 <result pre="influenza vaccines and circulating strains occurs regularly, resulting in severe" exact="influenza" post="seasons (1). It is also recognized that HA-based influenza"/>
 <result pre="severe influenza seasons (1). It is also recognized that HA-based" exact="influenza" post="vaccine technology cannot respond swiftly to emerging pandemic viruses,"/>
 <result pre="the 2009 H1N1 pandemic. Therefore, it is imperative to develop" exact="influenza" post="vaccines with the ability to induce enduring broadly protective"/>
 <result pre="induce enduring broadly protective immunity against matched and mismatched seasonal" exact="influenza" post="virus strains and that can be produced rapidly in"/>
 <result pre="In recent years, new strategies for the development of novel" exact="influenza" post="vaccines conferring superior length and breadth of protection have"/>
 <result pre="antibodies targeting the more highly conserved stem region of the" exact="influenza" post="virus HA protein (7, 8). Attention has also recently"/>
 <result pre="Attention has also recently been focused on immunity elicited by" exact="influenza" post="virus neuraminidase (NA), which is less variable than HA,"/>
 <result pre="based on the conserved ectodomain of matrix protein 2 of" exact="influenza" post="virus have been evaluated previously in multiple reports (11,"/>
 <result pre="evaluated previously in multiple reports (11, 12). Another strategy in" exact="influenza" post="vaccine research focuses on using live attenuated influenza viruses"/>
 <result pre="strategy in influenza vaccine research focuses on using live attenuated" exact="influenza" post="viruses (LAIVs) to mimic natural infection and induce both"/>
 <result pre="natural infection and induce both humoral and cellular immunity to" exact="influenza" post="virus. A cold-adapted LAIV (Influenza Mist) has been licensed"/>
 <result pre="aim to induce HA-specific neutralizing or stem-targeting antibodies to block" exact="influenza" post="virus, LAIVs elicit multifaceted immune responses through limited virus"/>
 <result pre="able to induce broader cross protective immunity than current inactivated" exact="influenza" post="vaccines. It has long been questioned why natural infections"/>
 <result pre="vaccines. It has long been questioned why natural infections with" exact="influenza" post="virus fail to induce broad and long-lasting immunity against"/>
 <result pre="immunity and interference with the induction of adaptive immunity during" exact="influenza" post="virus infection (19, 20). A role for NS1 in"/>
 <result pre="considered a desirable strategy for making safer and more immunogenic" exact="influenza" post="vaccines (22). An NS1-truncated vaccine induces strong immune responses"/>
 <result pre="of H3N2 or H1N1 viruses also cross protect against swine" exact="influenza" post="viruses in pigs (25–27), further highlighting the potential of"/>
 <result pre="preventing influenza. Furthermore, two clinical trials using deleted-NS1-trivalent LAIVs containing" exact="influenza" post="virus H1N1, H3N2, and B strains demonstrated induction of"/>
 <result pre="strain-specific and cross-neutralizing antibodies in vaccinated humans (28, 29). However," exact="influenza" post="viruses with truncated or deleted NS1 grow at relatively"/>
 <result pre="has hampered the commercial development of deleted-NS1 (DelNS1) live attenuated" exact="influenza" post="virus vaccine strains. Previous studies published by ourselves and"/>
 <result pre="acquisition of adaptive mutations that restore NS1-regulated M splicing during" exact="influenza" post="virus infection would increase virus replication ability in interferon-deficient"/>
 <result pre="sufficient quantities of DelNS1 viruses for use as live attenuated" exact="influenza" post="vaccines. It will also be important to evaluate if"/>
 <result pre="(31), we have established a panel of DelNS1 versions of" exact="influenza" post="A (2009 H1N1, H3N2, and H7N9) and B virus"/>
 <result pre="master donor strains derived from the 2009 H1N1 and HK2011" exact="influenza" post="B virus strains, respectively. We found that different strains"/>
 <result pre="B virus strains, respectively. We found that different strains of" exact="influenza" post="viruses utilize different adaptive strategies to support replication of"/>
 <result pre="of whether they originated from seasonal, pandemic, or highly pathogenic" exact="avian influenza" post="viruses, and are naturally cold-adapted. Importantly, immunization of mice"/>
 <result pre="whether they originated from seasonal, pandemic, or highly pathogenic avian" exact="influenza" post="viruses, and are naturally cold-adapted. Importantly, immunization of mice"/>
 <result pre="H5N1 or H7N9 viruses. Broad protection against antigenically distantly related" exact="influenza" post="viruses was also observed for DelNS1-H3N2 and DelNS1 B"/>
 <result pre="and for expressing additional antigens to enhance specific immunity against" exact="influenza" post="viruses. DelNS1 LAIVs with adaptive mutations enabling growth in"/>
 <result pre="more-effective and broadly protective vaccines for seasonal and emerging pandemic" exact="influenza" post="viruses. RESULTS Generation of 2009 H1N1 DelNS1 virus with"/>
 <result pre="humans and has become one of the two prevalent seasonal" exact="influenza" post="A viruses. We consider this to be an ideal"/>
 <result pre="an ideal virus from which to make a backbone for" exact="influenza" post="A DelNS1 LAIV. Using technology similar to that previously"/>
 <result pre="spontaneous and is a desirable feature in a live attenuated" exact="influenza" post="virus vaccine. To further verify the contribution of the"/>
 <result pre="attenuates the pathogenic properties of both seasonal and highly pathogenic" exact="avian influenza" post="viruses. FIG 2 Avirulence of CA4-DelNS1 virus. (A) A549"/>
 <result pre="the pathogenic properties of both seasonal and highly pathogenic avian" exact="influenza" post="viruses. FIG 2 Avirulence of CA4-DelNS1 virus. (A) A549"/>
 <result pre="challenge. To assess the protective ability of DelNS1 virus in" exact="influenza" post="virus infection, we immunized mice once with CA4-DelNS1 virus,"/>
 <result pre="vaccinated mice at day 3 postchallenge (Fig. 3B). Highly pathogenic" exact="avian influenza" post="H5N1 virus infection is fatal in approximately 60% of"/>
 <result pre="mice at day 3 postchallenge (Fig. 3B). Highly pathogenic avian" exact="influenza" post="H5N1 virus infection is fatal in approximately 60% of"/>
 <result pre="(Fig. S3A to C). Cross protective immunity against antigenically distinct" exact="influenza" post="A strains was also induced by CA4-DelNS1 (H1N1) and"/>
 <result pre="H1N1 strain, no significant DI genomes were detected from either" exact="influenza" post="A or influenza B DelNS1 LAIV (Fig. S2E). These"/>
 <result pre="significant DI genomes were detected from either influenza A or" exact="influenza" post="B DelNS1 LAIV (Fig. S2E). These results show that"/>
 <result pre="LAIV (Fig. S2E). These results show that DelNS1 live attenuated" exact="influenza" post="virus induces sustained and highly protective immunity against lethal"/>
 <result pre="that deletion of NS1 from CA4 created a live attenuated" exact="influenza" post="vaccine that seems to be more cross protective than"/>
 <result pre="LAIVs can elicit immunity that is sufficiently broad to overcome" exact="influenza" post="vaccine mismatches caused by antigenic drift of seasonal influenza"/>
 <result pre="overcome influenza vaccine mismatches caused by antigenic drift of seasonal" exact="influenza" post="viruses. 10.1128/mBio.02180-19.4FIG S4Viral titers in lungs of mice infected"/>
 <result pre="terms of the Creative Commons Attribution 4.0 International license. DelNS1" exact="influenza" post="B virus cross protects against different genetic lineages. To"/>
 <result pre="further evaluate the potential of DelNS1 LAIVs for use in" exact="influenza" post="vaccine applications, we generated a DelNS1 influenza B virus"/>
 <result pre="for use in influenza vaccine applications, we generated a DelNS1" exact="influenza" post="B virus using a master donor backbone from a"/>
 <result pre="virus using a master donor backbone from a Victoria lineage" exact="influenza" post="B virus, B/Hong Kong/8038/2011. The NS1 coding region was"/>
 <result pre="NS segment of B/Hong Kong/8038/2011, and a NS1-deleted version of" exact="influenza" post="B virus was rescued using a reverse genetics protocol"/>
 <result pre="5A) as described above. A NS1-deleted version of B/Hong Kong/8038/2011" exact="influenza" post="B virus adapted to replicate in MDCK cells and"/>
 <result pre="assay (Fig. S5A). Analysis of growth properties found that DelNS1-B8038" exact="influenza" post="B virus replicates at 33°C in MDCK cells but"/>
 <result pre="reduced replication efficiency at 37°C (Fig. 5C), similarly to CA4-DelNS1" exact="influenza" post="A viruses. DelNS1-B8038 LAIV cannot replicate in interferon-competent A549"/>
 <result pre="cells (Fig. 5C). There are two genetically distinct lineages of" exact="influenza" post="B viruses, namely, Victoria and Yamagata, cocirculating in humans."/>
 <result pre="cocirculating in humans. To assess if DelNS1-B8038, a Victoria lineage" exact="influenza" post="B virus, provides protection from infection with both lineages"/>
 <result pre="B virus, provides protection from infection with both lineages of" exact="influenza" post="B virus, mice were immunized once through the nasal"/>
 <result pre="route and were then (after 3 weeks) challenged with mouse-adapted" exact="influenza" post="B virus of either the Yamagata (B/Florida/4/2006) or Victoria"/>
 <result pre="is able to induce cross protective activity against antigenically distinct" exact="influenza" post="B virus strains. FIG 5 Generation and characterization of"/>
 <result pre="and characterization of DelNS1 B LAIV. (A) Generation of DelNS1-B8038" exact="influenza" post="B virus by reverse genetics. pHW2000 plasmids containing an"/>
 <result pre="the virus titer stabilized. (B) Adaptive mutations in growth-adapted DelNS1-B8038" exact="influenza" post="B virus. Mutations in PA (T210C), NA (T1429C), NP"/>
 <result pre="M (G88C plus A280G) were identified. (C) Growth of DelNS1-B8038" exact="influenza" post="B virus in cell culture. MDCK or A549 cells"/>
 <result pre="mice were challenged with mouse-adapted B/Brisbane/60/2008 (Victoria) or B/Florida/4/2006 (Yamagata)" exact="influenza" post="B virus at 10 MLD50. Body weight and survival"/>
 <result pre="10.1128/mBio.02180-19.5FIG S5Viral titers in lungs of mice infected with mouse-adapted" exact="influenza" post="B viruses. Download FIG S5, PDF file, 0.1 MB."/>
 <result pre="ca-LAIV-immunized mice. CD4+ and CD8+ T cells specific for conserved" exact="influenza" post="virus (NP) epitopes were analyzed using intracellular cytokine staining"/>
 <result pre="of the two for mediating cross protective cell immunity against" exact="influenza" post="virus infection. However, when CA4-DelNS1 LAIV-immunized mice were depleted"/>
 <result pre="immunities and that cross protective immunity was mainly mediated by" exact="influenza" post="virus-specific T cells. FIG 6 DelNS1 LAIV induces cross"/>
 <result pre="6 DelNS1 LAIV induces cross protective T cell responses against" exact="influenza" post="viruses. (A) Induction of antigen-specific CD8+ and CD4+ T"/>
 <result pre="protective immunity against challenge with H7N9, H5N1, and HK68 (H3N2)" exact="influenza" post="A viruses (Fig. 3; see also Fig. S2 and"/>
 <result pre="S3), no protection was observed when mice were challenged with" exact="influenza" post="B virus (Fig. 7B). This indicates that the cross"/>
 <result pre="the cross protective immunity induced by CA4-DelNS1 (H1N1) LAIV is" exact="influenza" post="A specific and does not extend to other types"/>
 <result pre="A specific and does not extend to other types of" exact="influenza" post="virus or to other viruses. Since NS1 is deleted"/>
 <result pre="in its place. We tested this possibility by expressing the" exact="influenza" post="B HA1 domain in the NS1 site of the"/>
 <result pre="BHA1 from the CA4-DelNS1 (H1N1) backbone (Fig. 7A). Expression of" exact="influenza" post="B virus HA1 was confirmed by Western blot analysis,"/>
 <result pre="7 mice in the group immunized with vaccine expressing the" exact="influenza" post="B HA1 antigen survived, while all mice immunized with"/>
 <result pre="These data highlight a novel strategy to improve the current" exact="influenza" post="vaccine regime by using DelNS1 LAIV to express additional"/>
 <result pre="viral antigens and thereby broaden and enhance specific immunity to" exact="influenza" post="viruses. FIG 7 DelNS1 LAIV expression of B-HA1 antigen"/>
 <result pre="expression of B-HA1 antigen protected against lethal challenge with both" exact="influenza" post="A and B viruses in mice. (A) Illustration of"/>
 <result pre="CA4-DelNS1 and then challenged 3 weeks later with mouse-adapted H1N1" exact="influenza" post="A virus (A/California/04/2009, 10 MLD50) or influenza B virus"/>
 <result pre="with mouse-adapted H1N1 influenza A virus (A/California/04/2009, 10 MLD50) or" exact="influenza" post="B virus (B/Brisbane/60/2008, 10 MLD50) and monitored for 14 days."/>
 <result pre="CA4-DelNS1 virus or CA4-DelNS1-BHA1, which contains the HA1 gene of" exact="influenza" post="B virus (B/Brisbane/60/2008) at the site in the NS"/>
 <result pre="7 (D) mice. 10.1128/mBio.02180-19.7FIG S7Construction of CA4-DelNS1 (H1N1) LAIV expressing" exact="influenza" post="B virus HA1. Download FIG S7, PDF file, 0.2"/>
 <result pre="Creative Commons Attribution 4.0 International license. DISCUSSION Currently available inactivated" exact="influenza" post="vaccines are suboptimal, particularly in the groups that are"/>
 <result pre="development of more highly effective and cross protective and long-lasting" exact="influenza" post="vaccines must be pursued. Influenza viruses in which the"/>
 <result pre="more immunogenic, due to the absence of the immune response" exact="suppression" post="usually mediated by the NS1 protein. With this assumption,"/>
 <result pre="this assumption, we established a panel of DelNS1 live attenuated" exact="influenza" post="viruses (LAIVs) bearing adaptive mutations that support their replication"/>
 <result pre="virus assistance. Master donor backbone viruses were established for both" exact="influenza" post="A virus and influenza B virus and were verified"/>
 <result pre="backbone viruses were established for both influenza A virus and" exact="influenza" post="B virus and were verified in in vitro and"/>
 <result pre="the lower temperature of 33°C. Given the rapid evolution of" exact="influenza" post="viruses and the uncertainty regarding the emergence of novel"/>
 <result pre="and the uncertainty regarding the emergence of novel strains, future" exact="influenza" post="vaccines should ideally provide cross protection against antigenically drifted"/>
 <result pre="against antigenically drifted viral strains and novel subtypes of zoonotic" exact="influenza" post="viruses. Our data strongly support the use of a"/>
 <result pre="more-effective and broader immunity for protection against seasonal and pandemic" exact="influenza" post="virus strains. We have shown DelNS1 H1N1, H3N2, and"/>
 <result pre="the capacity to express extra viral antigens will make better" exact="influenza" post="vaccines, addressing some critical pitfalls of existing products. One"/>
 <result pre="the advantages of LAIV vaccines over inactivated split or subunit" exact="influenza" post="virus vaccines is the ability to induce both humoral"/>
 <result pre="is one of the key criteria for seasonal and pandemic" exact="influenza" post="vaccines. The superior ability of LAIVs to induce potent"/>
 <result pre="are seronegative or who have not experienced previous infection with" exact="influenza" post="viruses, being shed at a comparatively high titer for"/>
 <result pre="below 2 years old, who are commonly naive with respect to" exact="influenza" post="virus infection. On the other hand, preexisting immunity from"/>
 <result pre="use of premature termination codons to attenuate or completely block" exact="influenza" post="virus replication in normal cells (6, 14–16). Those studies"/>
 <result pre="if such strategies can be applied in other subtypes of" exact="influenza" post="A or influenza B viruses, given that strain-specific adaptive"/>
 <result pre="can be applied in other subtypes of influenza A or" exact="influenza" post="B viruses, given that strain-specific adaptive mechanisms are relatively"/>
 <result pre="viruses, given that strain-specific adaptive mechanisms are relatively common in" exact="influenza" post="viruses. There is also concern regarding the stability of"/>
 <result pre="strains being regained during infection with LAIV vaccines. Live attenuated" exact="influenza" post="vaccines with modified NS1 or lacking the entire NS1"/>
 <result pre="or of individuals who had not previously been infected with" exact="influenza" post="virus. The safety features inherent with the removal of"/>
 <result pre="the LAIV vaccine for use against both seasonal and pandemic" exact="influenza" post="virus strains. Influenza virus is unique in its ability"/>
 <result pre="to induce high-level protective humoral and T cell responses to" exact="influenza" post="viruses. Our data show that cross protective immunity elicited"/>
 <result pre="rapidly, with more H3N2 epidemics being recorded than H1N1 or" exact="influenza" post="B virus epidemics in the years since H3N2 emerged"/>
 <result pre="challenge with HK68-MA virus. One strategy to improve the current" exact="influenza" post="vaccine regime is to induce immunities to multiple viral"/>
 <result pre="strain; we have demonstrated that expressing the HA1 domain of" exact="influenza" post="B virus in the CA4-DelNS1 system protects immunized mice"/>
 <result pre="vectors to express extra antigens to enhance specific immunity against" exact="influenza" post="or to serve as vaccines for other respiratory viruses."/>
 <result pre="and H3N2 LAIVs together with LAIVs representing either of the" exact="influenza" post="B virus lineages to optimize cross protection against wild-type"/>
 <result pre="H1N1 virus A/California/04/2009, H5N1 virus A/Vietnam/1194/2004, H7N9 virus A/Zhejiang/DTID-ZJU01/2013, and" exact="influenza" post="B virus B/HK/8038/2011 were rescued by reverse genetics (49,"/>
 <result pre="viruses were as described previously (35–37, 51). Cold-adapted live attenuated" exact="influenza" post="vaccine (ca-LAIV-H1N1) was purified from the Influenza Mist LAIV"/>
 <result pre="from the Influenza Mist LAIV vaccine available in the 2012" exact="influenza" post="season. Construction of plasmids. NS1 deletion plasmid pHW2000-DelNS1 was"/>
 <result pre="inverse PCR were 5′-GACATACTTATGAGGATGTC-3′ (CA4-DelNS1-F) and 5′-CTGAAAGCTTGACATGGTGTTG-3′ (CA4-DelNS1-R). Primers for" exact="influenza" post="B DelNS1 inverse PCR were 5′-CTCAATTTGTGTTGTGGTCATGTTGTCCGCC-3′ (Influenza b-DelNS1-F) and"/>
 <result pre="pHW2000 plasmids containing the DelNS1 segment and the other 7" exact="influenza" post="virus genomic segments, together with an NS1 expression plasmid,"/>
 <result pre="or A/Hong Kong/1/1968 virus were used for virus rescue. For" exact="influenza" post="B DelNS1 virus DelNS1-B8038, rescued virus was passaged 10"/>
 <result pre="(34). For comparisons, passaged CA4-DelNS1, commercial coadapted Flumist live attenuated" exact="influenza" post="vaccine (2014–2015 season), plaque-purified cold-adapted H1N1 CA7 from Flumist,"/>
 <result pre="100 PFU; for H7N9, 10 MLD50, 2 × 105 PFU; for mouse-adapted" exact="influenza" post="B/Florida/4/2006 virus, 10 MLD50, 5 × 105 PFU; for mouse-adapted influenza"/>
 <result pre="mouse-adapted influenza B/Florida/4/2006 virus, 10 MLD50, 5 × 105 PFU; for mouse-adapted" exact="influenza" post="B/Brisbane/60/2008 virus, 10 MLD50, 5 × 106 PFU; for mouse-adapted H3N2"/>
 <result pre="Xia N, Yuen K-Y, Chen H. 2019. Generation of DelNS1" exact="influenza" post="viruses: a strategy for optimizing live attenuated influenza vaccines."/>
 <result pre="of DelNS1 influenza viruses: a strategy for optimizing live attenuated" exact="influenza" post="vaccines. mBio 10:e02180-19. https://doi.org/10.1128/mBio.02180-19. ACKNOWLEDGMENTS We thank Robert Webster"/>
 <result pre="Ortega-SanchezIR, MessonnierML, ThompsonWW, WortleyPM, WeintraubE, BridgesCB2007The annual impact of seasonal" exact="influenza" post="in the US: measuring disease burden and costs. Vaccine25:5086–5096."/>
 <result pre="Immunol53:102–110. doi:10.1016/j.coi.2018.04.015.29734023 3.NachbagauerR, PaleseP2018Development of next generation hemagglutinin-based broadly protective" exact="influenza" post="virus vaccines. Curr Opin Immunol53:51–57. doi:10.1016/j.coi.2018.04.001.29680576 4.PetschB, SchneeM, VogelAB,"/>
 <result pre="KrampsT2012Protective efficacy of in vitro synthesized, specific mRNA vaccines against" exact="influenza" post="A virus infection. Nat Biotechnol30:1210–1216. doi:10.1038/nbt.2436.23159882 5.LiebowitzD, LindbloomJD, BrandlJR,"/>
 <result pre="doi:10.1038/nbt.2436.23159882 5.LiebowitzD, LindbloomJD, BrandlJR, GargSJ, TuckerSN2015High titre neutralising antibodies to" exact="influenza" post="after oral tablet immunisation: a phase 1, randomised, placebo-controlled"/>
 <result pre="Infect Dis15:1041–1048. doi:10.1016/S1473-3099(15)00266-2.26333337 6.BazM, BoonnakK, PaskelM, SantosC, PowellT, TownsendA, SubbaraoK2015Nonreplicating" exact="influenza" post="A virus vaccines confer broad protection against lethal challenge."/>
 <result pre="MeertenS, YuW, KoudstaalW, GoudsmitJ, WardAB, MeijbergW, WilsonIA, RadoševićK2015A stable trimeric" exact="influenza" post="hemagglutinin stem as a broadly protective immunogen. Science349:1301–1306. doi:10.1126/science.aac7263.26303961"/>
 <result pre="tenOeverBR, TanGS, SubramaniamS, PaleseP, KrammerF2017Broadly protective murine monoclonal antibodies against" exact="influenza" post="B virus target highly conserved neuraminidase epitopes. Nat Microbiol2:1415–1424."/>
 <result pre="SaelensX2011Universal vaccine based on ectodomain of matrix protein 2 of" exact="influenza" post="A: Fc receptors and alveolar macrophages mediate protection. J"/>
 <result pre="macrophages mediate protection. J Immunol186:1022–1031. doi:10.4049/jimmunol.0902147.21169548 12.KolpeA, SchepensB, FiersW, SaelensX2017M2-based" exact="influenza" post="vaccines: recent advances and clinical potential. Expert Rev Vaccines16:123–136."/>
 <result pre="BaiH, WuTT, WangJ, ShuY, SunR2018Genome-wide identification of interferon-sensitive mutations enables" exact="influenza" post="vaccine design. Science359:290–296. doi:10.1126/science.aan8806.29348231 15.SiL, XuH, ZhouX, ZhangZ, TianZ,"/>
 <result pre="WuY, ZhangB, NiuZ, ZhangC, FuG, XiaoS, XiaQ, ZhangL, ZhouD2016Generation of" exact="influenza" post="A viruses as live but replication-incompetent virus vaccines. Science354:1170–1173."/>
 <result pre="BloomBR, LiQ, DengJC, ZhouP, QinFX, ChengG2017Generation of a live attenuated" exact="influenza" post="vaccine that elicits broad protection in mice and ferrets."/>
 <result pre="mice and ferrets. Cell Host Microbe21:334–343. doi:10.1016/j.chom.2017.02.007.28279345 17.KrugRM2015Functions of the" exact="influenza" post="A virus NS1 protein in antiviral defense. Curr Opin"/>
 <result pre="WangX, BaslerCF, TaubenbergerJK, BumgarnerRE, PaleseP, KatzeMG, Garcia-SastreA2002Cellular transcriptional profiling in" exact="influenza" post="A virus-infected lung epithelial cells: the role of the"/>
 <result pre="KraussS, WebbyRJ, WebsterRG2017Molecular basis of mammalian transmissibility of avian H1N1" exact="influenza" post="viruses and their pandemic potential. Proc Natl Acad Sci"/>
 <result pre="Proc Natl Acad Sci U S A114:11217–11222. doi:10.1073/pnas.1713974114.28874549 22.RichtJA, Garcia-SastreA2009Attenuated" exact="influenza" post="virus vaccines with modified NS1 proteins. Curr Top Microbiol"/>
 <result pre="Immunol333:177–195. doi:10.1007/978-3-540-92165-3_9.19768406 23.MuellerSN, LangleyWA, CarneroE, Garcia-SastreA, AhmedR2010Immunization with live attenuated" exact="influenza" post="viruses that express altered NS1 proteins results in potent"/>
 <result pre="JankeBH, WuWH, YoonKJ, WebbyRJ, SolorzanoA, Garcia-SastreA2006Vaccination of pigs against swine" exact="influenza" post="viruses by using an NS1-truncated modified live-virus vaccine. J"/>
 <result pre="HenningsonJN, LorussoA, VincentAL, LovingCL, RothJA, KehrliMEJr.2012Vaccination with NS1-truncated H3N2 swine" exact="influenza" post="virus primes T cells and confers cross-protection against an"/>
 <result pre="MaW, LagerKM, RichtJA, JankeBH, SandbulteMR, GaugerPC, LovingCL, WebbyRJ, Garcia-SastreA2012Live attenuated" exact="influenza" post="vaccine provides superior protection from heterologous infection in pigs"/>
 <result pre="infection in pigs with maternal antibodies without inducing vaccine-associated enhanced" exact="respiratory disease." post="J Virol86:10597–10605. doi:10.1128/JVI.01439-12.22811541 28.MosslerC, GroissF, WolztM, WolschekM, SeipeltJ, MusterT2013Phase"/>
 <result pre="WolztM, WolschekM, SeipeltJ, MusterT2013Phase I/II trial of a replication-deficient trivalent" exact="influenza" post="virus vaccine lacking NS1. Vaccine31:6194–6200. doi:10.1016/j.vaccine.2013.10.061.24183981 29.WacheckV, EgorovA, GroissF,"/>
 <result pre="RoethlE, MorokuttiA, WolschekM, FerkoB, SeipeltJ, Dick-GudenusR, MusterT2010A novel type of" exact="influenza" post="vaccine: safety and immunogenicity of replication-deficient influenza virus created"/>
 <result pre="novel type of influenza vaccine: safety and immunogenicity of replication-deficient" exact="influenza" post="virus created by deletion of the interferon antagonist NS1."/>
 <result pre="30.EgorovA, BrandtS, SereinigS, RomanovaJ, FerkoB, KatingerD, GrassauerA, AlexandrovaG, KatingerH, MusterT1998Transfectant" exact="influenza" post="A viruses with long deletions in the NS1 protein"/>
 <result pre="of the M segment of viral RNA supports replication of" exact="influenza" post="virus with an NS1 deletion by modulating alternative splicing"/>
 <result pre="ReiterM, NakowitschS, HumerJ, MorokuttiA, MusterT, EgorovA, KittelC2009Development of a live-attenuated" exact="influenza" post="B DeltaNS1 intranasal vaccine candidate. Vaccine27:2851–2857. doi:10.1016/j.vaccine.2009.02.087.19366569 33.van WielinkR,"/>
 <result pre="M-gene segment can substantially increase replication efficiency of NS1 deletion" exact="influenza" post="A virus in MDCK cells. J Virol86:12341–12350. doi:10.1128/JVI.01725-12.22951840 34.GouldPS,"/>
 <result pre="in MDCK cells. J Virol86:12341–12350. doi:10.1128/JVI.01725-12.22951840 34.GouldPS, EastonAJ, DimmockNJ2017Live attenuated" exact="influenza" post="vaccine contains substantial and unexpected amounts of defective viral"/>
 <result pre="LiuH, KitLC, BairdS, NesrallahM2001Pattern of mutation in the genome of" exact="influenza" post="A virus on adaptation to increased virulence in the"/>
 <result pre="NichollsJM, GuanY, WaldmannTA, PeirisJS, PereraLP, PoonLL2014IL-15 adjuvanted multivalent vaccinia-based universal" exact="influenza" post="vaccine requires CD4+ T cells for heterosubtypic protection. Proc"/>
 <result pre="multimechanistic antibody targeting the receptor binding site potently cross-protects against" exact="influenza" post="B viruses. Sci Transl Med doi:10.1126/scitranslmed.aam5752. 38.BelongiaEA, SimpsonMD, KingJP,"/>
 <result pre="Transl Med doi:10.1126/scitranslmed.aam5752. 38.BelongiaEA, SimpsonMD, KingJP, SundaramME, KelleyNS, OsterholmMT, McLeanHQ2016Variable" exact="influenza" post="vaccine effectiveness by subtype: a systematic review and meta-analysis"/>
 <result pre="challenges and solutions. Cell Host Microbe17:295–300. doi:10.1016/j.chom.2015.02.012.25766291 40.JinH, SubbaraoK2015Live attenuated" exact="influenza" post="vaccine. Curr Top Microbiol Immunol386:181–204. doi:10.1007/82_2014_410.25059893 41.MurphyBR, CoelinghK2002Principles underlying"/>
 <result pre="CoelinghK2002Principles underlying the development and use of live attenuated cold-adapted" exact="influenza" post="A and B virus vaccines. Viral Immunol15:295–323. doi:10.1089/08828240260066242.12081014 42.CoelinghKL,"/>
 <result pre="Viral Immunol15:295–323. doi:10.1089/08828240260066242.12081014 42.CoelinghKL, LukeCJ, JinH, TalaatKR2014Development of live attenuated" exact="influenza" post="vaccines against pandemic influenza strains. Expert Rev Vaccines13:855–871. doi:10.1586/14760584.2014.922417.24867587"/>
 <result pre="LukeCJ, JinH, TalaatKR2014Development of live attenuated influenza vaccines against pandemic" exact="influenza" post="strains. Expert Rev Vaccines13:855–871. doi:10.1586/14760584.2014.922417.24867587 43.HeatonNS, SachsD, ChenCJ, HaiR,"/>
 <result pre="Rev Vaccines13:855–871. doi:10.1586/14760584.2014.922417.24867587 43.HeatonNS, SachsD, ChenCJ, HaiR, PaleseP2013Genome-wide mutagenesis of" exact="influenza" post="virus reveals unique plasticity of the hemagglutinin and NS1"/>
 <result pre="U S A110:20248–20253. doi:10.1073/pnas.1320524110.24277853 44.CarrilloB, ChoiJM, BornholdtZA, SankaranB, RiceAP, PrasadBV2014The" exact="influenza" post="A virus protein NS1 displays structural polymorphism. J Virol88:4113–4122."/>
 <result pre="LiuH, ChenY, SongW, YuenKY, ChenH2017An NS-segment exonic splicing enhancer regulates" exact="influenza" post="A virus replication in mammalian cells. Nat Commun8:14751. doi:10.1038/ncomms14751.28323816"/>
 <result pre="NguyenTH, WertheimHFL, HurtAC, OsterhausA, BarrIG, FouchierRAM, HorbyPW, SmithDJ2014Antibody landscapes after" exact="influenza" post="virus infection or vaccination. Science346:996–1000. doi:10.1126/science.1256427.25414313 47.SmithDJ, LapedesAS, de"/>
 <result pre="BestebroerTM, RimmelzwaanGF, OsterhausAD, FouchierRA2004Mapping the antigenic and genetic evolution of" exact="influenza" post="virus. Science305:371–376. doi:10.1126/science.1097211.15218094 48.BedfordT, RileyS, BarrIG, BroorS, ChadhaM, CoxNJ,"/>
 <result pre="SuchardMA, TashiroM, WangD, XuX, LemeyP, RussellCA2015Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic drift. Nature523:217–220. doi:10.1038/nature14460.26053121 49.HoffmannE, NeumannG,"/>
 <result pre="NeumannG, KawaokaY, HobomG, WebsterRG2000A DNA transfection system for generation of" exact="influenza" post="A virus from eight plasmids. Proc Natl Acad Sci"/>
 <result pre="in viral protein PB2 enhances the effects of E627K on" exact="influenza" post="virus replication. Nat Commun5:5509. doi:10.1038/ncomms6509.25409547 51.ZhengB, ChanKH, ZhangAJ, ZhouJ,"/>
 <result pre="WooPC, ChanJF, ToKK, ChenH, YuenKY2010D225G mutation in hemagglutinin of pandemic" exact="influenza" post="H1N1 (2009) virus enhances virulence in mice. Exp Biol"/>
 <result pre="LambertK, TakimotoT, TophamDJ2011T cell-mediated protection against lethal 2009 pandemic H1N1" exact="influenza" post="virus infection in a mouse model. J Virol85:448–455. doi:10.1128/JVI.01812-10.20980523"/>
</results>
